Veytics Intelligence
2026-09-15 · Yahoo

Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.